Xeris Pharmaceuticals | XERS - Debt


Xeris Pharmaceuticals reported $258.55M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Celltrion KRW 160.58B 733.3M Mar/2026
Cspc Pharmaceutical CNY 641.11M 146.11M Dec/2025
Deva Holding AS TRY 5.3B 871.93M Sep/2023
Dianthus Therapeutics USD 1.36M 79K Mar/2026
Divis Laboratories Ltd INR 70M 30M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Kangmei Pharma CNY 173.71M 42.08M Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 100K 0 Dec/2023
Medical Developments International AUD 1.99M 152K Jun/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Organigram Holdings CAD 8.2M 554K Mar/2026
Ovoca Bio EUR 0 0 Jun/2021
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.63B 7.7M Mar/2026
Pharma Mar EUR 45.84M 1.7M Jun/2026
Qiagen NV USD 1.65B 165.82M Mar/2026
Sartorius EUR 4.05B 248.8M Jun/2026
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Supernus Pharmaceuticals USD 40.9M 74K Mar/2026
Tilray USD 640.95M 35.17M Jun/2022
Zealand Pharma A/S 414M 8.23M Mar/2026
Zz Pientze Pharmaceu CNY 1.07B 2.82M Mar/2026